Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-Lledó, Alberto
dc.contributor.authorMartín Delgado, María Cruz
dc.contributor.authorBouza, Emilio
dc.date.accessioned2022-08-05T09:14:27Z
dc.date.available2022-08-05T09:14:27Z
dc.date.issued2022
dc.identifier.issn0214-3429spa
dc.identifier.urihttp://hdl.handle.net/10641/3087
dc.description.abstractThe precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.spa
dc.language.isoengspa
dc.publisherRevista Española de Quimioterapiaspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titlePharmacological treatment of COVID-19: an opinion paper.spa
dc.typejournal articlespa
dc.type.hasVersionSMURspa
dc.rights.accessRightsopen accessspa
dc.description.extent258 KBspa
dc.identifier.doi10.37201/req/158.2021spa
dc.relation.publisherversionhttps://seq.es/abstract/rev-esp-quimioter-2021-december-11-2/spa


Ficheros en el ítem

FicherosTamañoFormatoVer
2.- Pharmacological treatment ...257.9KbPDFVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España